Form 4: CytomX Therapeutics CEO Exercises Stock Options and Acquires Shares

CytomX Therapeutics CEO Sean A. McCarthy exercised stock options and acquired shares of common stock on March 26, 2024.

Summary

• On March 26, 2024, Sean A. McCarthy, CEO of CytomX Therapeutics, exercised stock options to acquire 109,768 shares of common stock at a price of $1.5749 per share.
• Following the transaction, McCarthy directly owns 634,249 shares of common stock, including 197,500 restricted stock units.
• McCarthy also indirectly owns 93,158 shares through the Sean A. McCarthy 2018 Trust, where he serves as trustee.
• The exercised stock option was fully vested and exercisable.
• McCarthy previously transferred 9,768 shares subject to this stock option to a family member.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard insider transaction. The CEO exercising options could be seen as a positive sign, but it's not definitively bullish.

Positives

• The CEO's exercise of stock options could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like the CEO, make transactions involving the company's securities. These filings provide transparency to the market.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence from the CEO.

Key Dates